Single molecule electronic multiplex snp assay and pcr analysis

US2017058335A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2017058335-A1
Application numberUS-201515118812-A
CountryUS
Kind codeA1
Filing dateFeb 12, 2015
Priority dateFeb 12, 2014
Publication dateMar 2, 2017
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention provides methods of using labeled primers or probes for nucleic acid target detection and to detect the identity or presence of a nucleotide at certain positions in nucleic acid sequences with single molecule sensitivity using nanopore detection, and sets of oligonucleotide primers for use in such methods, as well as methods of quantitative PCR coupled with nanopore detection.

First claim

Opening claim text (preview).

What is claimed is: 1 . A method for identifying a single nucleotide residue of interest at a position within a stretch of consecutive nucleotide residues in a DNA, comprising the steps of: (a) incubating the DNA with (1) at least one oligonucleotide primer, each primer comprising a removably attached label (i) corresponding to a particular primer sequence, and (ii) having a unique signature detectable by a nanopore, wherein the nucleotides in the primer that are 5′ to the nucleotide at the 3′-terminus of the primer are substantially fully complementary to the nucleotides in the DNA immediately 3′ to the single nucleotide of interest, (2) terminating nucleotides, and (3) DNA polymerase,  so as to perform a single base extension of a primer whose 3′ terminal nucleotide hybridized to the single nucleotide residue of interest in the DNA, if such a primer was present, using the terminating nucleotide, thereby forming an extension product of the primer which had a 3′ nucleotide complementary to the nucleotide of interest in the DNA; (b) removing the label from the extension product, if present; (c) detecting by nanopore the signature of the label of the primer whose 3′ terminal nucleotide hybridized to the single nucleotide residue of interest, so as to identify the label and primer, if present; thereby identifying the single nucleotide residue of interest. 2 . The method of claim 1 , wherein the DNA is a single-stranded DNA, or is a double-stranded DNA. 3 . The method of any one of claims 1 - 2 , wherein in step (a) the DNA is incubated with a plurality of oligonucleotide primers, wherein the plurality of oligonucleotide primers comprises at least two primers, at least three primers, or at least four primers having (i) identical nucleotide sequences except for having a different nucleotide at the 3′ terminus of each of the primers, wherein the identical nucleotides in each of the primers are substantially fully complementary to the nucleotides in the DNA immediately 3′ to the single nucleotide residue of interest. 4 . The method of any one of claims 1 - 3 , wherein the terminating nucleotides are dideoxynucleotides, wherein the terminating nucleotides comprise a hook, wherein the terminating nucleotides comprise a hook which is a biotin moiety, or wherein the terminating nucleotides comprise a hook which is a phenylboronic acid (PBA) moiety. 5 . The method of any one of claims 1 - 4 , wherein prior to removing the label, the extension product is separated from the unextended primers, or wherein prior to removing the label, the extension product is separated from the unextended primers by capturing the extension product on streptavidin-coated magnetic beads, or wherein prior to removing the label, the extension product is separated from the unextended primers by capturing the extension product on salicylhydroxamic acid (SHA)-coated magnetic beads. 6 . The method of any one of claims 1 - 5 , wherein the label is removably attached via a cleavable linker, or is removably attached via a cleavable linker which is an azido linker, or is removably attached via a cleavable linker which is cleaved in step (b) by a phosphine-containing moiety or by tris-(2-carboxyethyl)phosphine (TCEP), or is removably attached via a cleavable linker which is attached to the 5′-terminus of the oligonucleotide primer between the label and the oligonucleotide. 7 . The method of any one of claims 1 - 6 , wherein the label comprises one or more of ethylene glycol, an amino acid, a carbohydrate, a peptide, a dye, a chemiluminiscent compound, a mononucleotide, a dinucleotide, a trinucleotide, a tetranucleotide, a pentanucleotide, a hexanucleotide, an aliphatic acid, an aromatic acid, an alcohol, a thiol group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an azido group, or a combination thereof. 8 . The method of any one of claims 1 - 7 , wherein the labels are polyethylene glycol (PEG) labels, or are PEG labels which each have a different length from each other. 9 . The method of any one of claims 1 - 8 , wherein the DNA is incubated with a plurality of primers, or at least 20 different oligonucleotide primers, each primer comprising an attached label having a unique signature detectable by a nanopore. 10 . The method of any one of claims 1 - 9 , wherein the nanopore is biological, is proteinaceous, comprises alpha hemolysin, is a solid-state nanopore, or is in a solid-state membrane. 11 . The method of any one of claims 1 - 10 , wherein the signature is an electronic signature, or is an electrical current blockade signature. 12 . The method of any one of claims 1 - 11 , wherein the nucleotide sequence of the portion of each primer which is 5′ to the 3′ nucleotide of the primer is at least 85% complementary, is at least 90% complementary, is at least 95% complementary, or is 100% complementary to the sequence of the DNA which is 3′ to the single nucleotide residue of interest. 13 . The method of any one of claims 1 - 12 , wherein the sequence of the primer is 10-40 nucleotides long, or is 18-24 nucleotides long. 14 . The method of any one of claims 1 - 13 , wherein the single nucleotide of interest is at the site of a single nucleotide polymorphism (SNP). 15 . An assay for performing the method of any one of claims 1 - 14 . 16 . A set of oligonucleotide primers, wherein each primer comprises a removably attached label (1) corresponding to a particular primer sequence, and (2) having a unique signature detectable by a nanopore, wherein the set comprises at least two primers, at least three primers, or at least four primers having (i) identical nucleotide sequences except for having a different nucleotide at the 3′ terminus of each of the primers, and (ii) a different label corresponding to the different nucleotide at the 3′ terminus, wherein the identical nucleotides in each of the primers are substantially fully complementary to the nucleotides in a strand of DNA immediately 3′ to a single nucleotide residue of interest. 17 . A set of oligonucleotide primers, wherein each primer comprises a removably attached label (1) corresponding to a particular primer sequence, and (2) having a unique signature detectable by a nanopore; and wherein the 3′ nucleotide of each primer is complementary to a single nucleotide residue of interest in a strand of DNA and the other nucleotides in that primer are substantially fully complementary to the nucleotides in the DNA immediately 3′ of the single nucleotide residue of interest. 18 . The set of oligonucleotide primers of any one of claims 16 - 17 , wherein the single nucleotide residue of interest is at a site of a single nucleotide polymorphism (SNP). 19 . The set of oligonucleotide primers of any one of claims 16 - 18 , wherein the sequence of each primer is 15-40 nucleotides long, or is 18-24 nucleotides long. 20 . The set of oligonucleotide primers of any one of claims 16 - 19 , wherein each removably attached label comprises one or more of ethylene glycol, an amino acid, a carbohydrate, a peptide, a dye, a chemiluminiscent compound, a mononucleotide, a dinucleotide, a trinucleotide, a tetranucleotide, a pentanucleotide, a hexanucleotide, an aliphatic acid, an aromatic acid, an alcohol, a thiol group, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an azido group, or a combination thereof. 21 . The set of oligonucleotide primers of any one of claims 16 - 20 , wherein the removably attached labe

Assignees

Inventors

Classifications

  • C12Q1/6858Primary

    Allele-specific amplification · CPC title

  • using modified primers or templates · CPC title

  • incorporating a non-extendable or blocking moiety · CPC title

  • being a biochannel or pore · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2017058335A1 cover?
This invention provides methods of using labeled primers or probes for nucleic acid target detection and to detect the identity or presence of a nucleotide at certain positions in nucleic acid sequences with single molecule sensitivity using nanopore detection, and sets of oligonucleotide primers for use in such methods, as well as methods of quantitative PCR coupled with nanopore detection.
Who is the assignee on this patent?
Tao Chuanjuan, Kumar Shiv, Chien Minchen, and 2 more
What technology area does this patent fall under?
Primary CPC classification C12Q1/6858. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Mar 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).